Evidence map›Paper›PMID 39411947›Full record

ReviewCurrent medicinal chemistry2025

Astaxanthin is a Novel Candidate for Glioblastoma Treatment? A Review.

Arian Rezaee, Mehrsa Radmanesh, Atena Asghari, Ahmad Nazari, Amir Abbas Shahidi, Amir Modarresi Chahardehi, Reza Arefnezhad, Tahereh Farkhondeh, Mohammad Saminin, Saeed Samarghandian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Arian RezaeeStudent Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mehrsa RadmaneshSchool of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Atena AsghariFaculty of Medicine, China Medical University, Shenyang, China.
Ahmad NazariFaculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Amir Abbas ShahidiStudent Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Amir Modarresi ChahardehiInfectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Reza ArefnezhadCoenzyme R Research Institute, Tehran, Iran.
Tahereh FarkhondehGeriatric Health Research Center, School of Pharmacy, Birjand University of Medical Sciences, Iran.
Mohammad SamininDepartment of Neurosurgery, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Saeed SamarghandianDepartment of Medical Physiology, Faculty of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is a malignant primary brain tumor with a poor prognosis and high recurrence rates. At present, the current treatments available for GBM patients can only prolong their overall survival and cannot provide a complete cure. Discovering an effective therapy against the disease is a challenge due to its recurrence and resistance to common available treatments for GBM. Several natural products have been documented to possess the potential to function as anticancer agents through diverse mechanisms. Astaxanthin (AXT) is an orange-red pigment that is a natural lipophilic and xanthophyll carotenoid derived mostly from microalgae. Numerous studies have examined that AXT impacts GBM cells in laboratory settings and animal models. This review aims to provide the latest information about the potential of astaxanthin as a novel therapeutic option for GBM. AXT has been targeted more on reactive oxygen species (ROS), and suppressed tumor growth in vitro and in vivo conditions. The available data suggests that AXT might serve as a key component in the development of innovative cancer therapies, especially for glioblastoma.

Indexed as

Antineoplastic AgentsBrain NeoplasmsGlioblastomaAnimalsHumansReactive Oxygen SpeciesXanthophyllsAntineoplastic AgentsastaxanthineReactive Oxygen SpeciesXanthophyllsanticancer agents.astaxanthincarotenoidGlioblastomanatural producttherapy

Identifiers

PMID39411947

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.